Every 10-Q that Sotera Health Company (SHC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SHC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SHC filings page.
Sotera Health Company reported strong growth for the three and six months ended June 30, 2026. Net revenues reached $321.4 million in Q2 2026, up 9.2%, and $601.4 million for the first half, up 9.6%, driven by pricing and volume gains across Sterigenics, Nordion and Nelson Labs, and higher Cobalt-60 product sales.
Q2 net income was $53.6 million versus $8.0 million a year earlier, and first‑half net income was $80.2 million versus a prior‑year loss, helped by higher gross profit, sharply lower amortization of intangibles and reduced interest expense. Adjusted EBITDA rose to $165.7 million in Q2 and $300.4 million year‑to‑date.
Cash and cash equivalents were $356.7 million and operating cash flow $117.9 million in the first half, alongside $92.6 million of capital expenditures, mainly in Sterigenics. Net long‑term debt was about $2.13 billion, with a largely undrawn $600 million revolver. The company continues to face ethylene‑oxide‑related tort litigation in several U.S. jurisdictions, which it is vigorously defending.
Sotera Health Company reported stronger Q1 2026 results. Net revenues were $280.0 million, up 10.0% from $254.5 million a year earlier, driven by pricing gains and higher volumes at Sterigenics and Nordion.
The company generated net income of $26.6 million, compared with a net loss of $13.3 million in Q1 2025, when results were burdened by a $30.9 million Illinois ethylene oxide litigation settlement. Adjusted Net Income rose to $52.4 million and Adjusted EBITDA to $134.7 million. Cash and cash equivalents were $315.9 million, against $2.14 billion of long-term debt, leaving the business still highly leveraged while it continues to face ongoing EO tort litigation in multiple states.
Sotera Health (SHC) reported stronger Q3 2025 results. Total revenue reached $311.3 million, up from $285.5 million a year ago, as Sterigenics and Nordion grew while Nelson Labs remained steady. Net income rose to $48.4 million from $17.0 million, with diluted EPS of $0.17 versus $0.06. For the first nine months, revenue was $860.2 million and net income was $43.1 million.
Cash generation and balance sheet improved. Year‑to‑date operating cash flow was $184.1 million, supporting capital spending and debt management. Long‑term debt declined to $2.129 billion from $2.208 billion. In September, the company repriced its term loan to Adjusted Term SOFR plus 2.50% and applied $75.0 million of cash to reduce borrowings; the average term‑loan rate fell to 7.22% in Q3 from 8.56% last year. Liquidity remained solid with $591.9 million available on the revolver.
Notable items. The company recorded $64.9 million year‑to‑date for Illinois EO litigation settlements and listed a $34.0 million related reserve in accrued liabilities at quarter‑end. Nordion’s Class 1B nuclear license was renewed for 25 years in September 2025. Shares outstanding were 284.1 million as of October 28, 2025.
Sotera Health reported consolidated net revenues of $294.3 million for the three months ended June 30, 2025, up from $276.6 million a year earlier, driven by higher service revenue in Sterigenics and steady contributions from Nordion and Nelson Labs. Gross profit rose to $166.6 million versus $152.8 million, and cash and cash equivalents increased to $332.4 million from $277.2 million at year-end, supporting liquidity.
The company recorded $34.0 million of Illinois EO litigation settlements during the quarter and established a $64.9 million reserve reflected in accrued liabilities and operating cash flows. Net income for the quarter was $8.0 million (basic EPS $0.03), while the six-month period produced a net loss of $5.3 million compared with net income of $15.1 million in the prior year period. Total assets were $3.217 billion, total liabilities $2.705 billion, and total equity improved to $511.3 million.